Artiva Biotherapeutics (ARTV) Institutional Ownership $10.51 -1.19 (-10.17%) (As of 11/14/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Institutional Ownership Changes (13F Filings) for Artiva Biotherapeutics (NASDAQ:ARTV)Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$1.48MNumber ofInstitutional Sellers(last 12 months)0 Get ARTV Insider Trade Alerts Want to know when executives and insiders are buying or selling Artiva Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad Crypto 101 MediaMusk Says ‘Dollar Will Be Worth Nothing…’Cash In On the Pro-Crypto America 27 experts reveal their top picks for 2025 Click here to reserve your seat at the Crypto Community Summit. Artiva Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/14/2024Acuta Capital Partners LLC44,000$680K0.6%N/A0.181% 11/14/2024MetLife Investment Management LLC8,733$135K0.0%N/A0.036% 11/13/2024BNP Paribas Financial Markets2,728$42K0.0%N/A0.011% 11/12/2024 Charles Schwab Investment Management Inc.40,293$623K0.0%N/A0.166% (Data available from 1/1/2016 forward) ARTV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ARTV shares? During the previous two years, the following institutional investors and hedge funds held shares of Artiva Biotherapeutics shares: Acuta Capital Partners LLC ($680K), Charles Schwab Investment Management Inc. ($623K), and MetLife Investment Management LLC ($135K), BNP Paribas Financial Markets ($42K).Learn more on ARTV's institutional investors. Which institutional investors have been buying Artiva Biotherapeutics stock? The following institutional investors have purchased Artiva Biotherapeutics stock in the last 24 months: Acuta Capital Partners LLC ($44K), Charles Schwab Investment Management Inc. ($40.29K), MetLife Investment Management LLC ($8.73K), and BNP Paribas Financial Markets ($2.73K). How much institutional buying is happening at Artiva Biotherapeutics? Institutional investors have bought a total of 95,754 shares in the last 24 months. This purchase volume represents approximately $1.48M in transactions. Related Companies IMTX Major Shareholders CRGX Major Shareholders MESO Major Shareholders AUTL Major Shareholders LENZ Major Shareholders CGEM Major Shareholders ADPT Major Shareholders REPL Major Shareholders RLAY Major Shareholders AVXL Major Shareholders This page (NASDAQ:ARTV) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | SponsoredTrump Win = "Bull Trap"?Dan's research shows that the last time the market looked this way, not only did our economy suffer a large su...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
